Cantor Fitzgerald Forecasts ARCT FY2025 Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for Arcturus Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the biotechnology company will post earnings of ($3.21) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Arcturus Therapeutics' current full-year earnings is ($2.31) per share.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.44. The firm had revenue of $41.67 million for the quarter, compared to analysts' expectations of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same period in the prior year, the business posted ($0.61) earnings per share.

Separately, HC Wainwright reiterated a "buy" rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research report on Monday, January 13th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $66.75.

Arcturus Therapeutics Stock Performance

NASDAQ ARCT traded up $0.68 on Thursday, hitting $17.42. The stock had a trading volume of 402,480 shares, compared to its average volume of 396,941. The firm has a 50-day moving average of $17.27 and a 200-day moving average of $19.74. The company has a market capitalization of $471.91 million, a price-to-earnings ratio of -7.85 and a beta of 2.63. Arcturus Therapeutics has a 52-week low of $14.30 and a 52-week high of $45.00.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of large investors have recently added to or reduced their stakes in ARCT. nVerses Capital LLC bought a new position in shares of Arcturus Therapeutics during the third quarter valued at about $42,000. China Universal Asset Management Co. Ltd. boosted its holdings in Arcturus Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company's stock valued at $121,000 after acquiring an additional 2,038 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Arcturus Therapeutics during the 2nd quarter worth approximately $142,000. Point72 DIFC Ltd bought a new position in Arcturus Therapeutics during the 2nd quarter worth approximately $188,000. Finally, SG Americas Securities LLC purchased a new position in Arcturus Therapeutics in the 3rd quarter worth approximately $191,000. Hedge funds and other institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.